CTDs are a heterogeneous group of diseases characterized by abnormal structure or function of one or more of the elements of connective tissue. Differential diagnosis of CTDs is mainly based on clinical findings but is complicated by the similarity of their symptoms. Therefore, autoantibodies are useful markers to support the diagnosis or exclusion of CTDs. The most prominent CTDs are systemic lupus erythematosus (SLE; potentially affecting all organs), Sjögren’s syndrome (SS; characterized by diminished lacrimal and salivary gland secretions), scleroderma (systemic sclerosis; a chronic, progressive dermatosis), limited systemic sclerosis (CREST syndrome), with a more benign disease course), poly-/dermatomyositis (PM/DM; an acute or chronic inflammatory disease of muscle and skin), and mixed connective tissue disease (MCTD; a syndrome with features of scleroderma, rheumatoid arthritis, SLE and PM/DM).
The CTD screen test contains the following tests: U1RNP, SS-A/Ro, SS-B/La, Centromere B, Scl-70, Jo-1, Fibrillarin, RNA Pol III, Rib-P, PM-Scl, PCNA, Mi-2, SmD and dsDNA
A positive CTD screen is further investigated for ds-DNA and ENA antibodies.
Coeliac disease is an autoimmune condition in which the ingestion of gluten, the water soluble wheat-gliadin and the prolamins in rye and barley causes chronic inflammation and damage to the small intestinal mucosa. IgA TTG has been identified as the major auto-antigen in coeliac disease.
IgA Tissue transglutaminase (TTG) is 90% specific for coeliac disease patients while endomysial antibodies (EMA) are 98% specific. Both have comparable disease sensitivity and both tests will detect >95% of coeliac patients
TTG screening will detect those patients with coeliac disease and positive results are confirmed with IgA endomysial antibody testing. Known coeliacs can be monitored by detection of tissue transglutaminase antibodies for dietary compliance.
It is important to ensure patients are on a gluten containing diet 6 weeks prior to testing to prevent false-negative results.
Patients with IgA deficiency can be tested for coeliac disease using the IgG tissue transglutaminase assay. Further IgG based coeliac disease testing can be performed determined on a case-by-case basis.
Antibodies to antigens in the dermo-epidermal junction are found in pemphigoid disease
These antibodies are also seen in Herpes Gestationis and in Dermatitis Herpetiformis
High titre antibodies to intercellular antigens in the stratified epithelium are found in pemphigus disease
These antibodies are also found in 5-10% of RA patients on penicillamine, the antibody disappears when the penicillamine is discontinued
They are also seen in some patients with cutaneous fungal infection or thermal burns
Though the diagnosis of DH is based on the appearance of the rash and IgA at the dermo-epidermal junction in the dermal papillac in biopsies, the presence of the antibodies associated with coeliac disease may point to the association of DH with gluten sensitivity (see Coeliac disease)
The term vasculitis refers to inflammation of blood vessels and represents a heterogeneous group of clinical disorders
Immunopathological mechanisms may be involved in primary (e.g. Wegener’s) and secondary vasculitides (e.g. infection, neoplasia, connective tissue disease, cryoglobulinaemia)
If there is evidence for more extensive visceral involvement, one of the primary systemic vasculitides may be involved
Alternatively, the vasculitis may be secondary to autoimmune disease (e.g. SLE, chronic active hepatitis), neoplasia (e.g. lymphoma), cryoglobulinaemia (these are immunoglobulins that form precipitates in the cold)
Some forms of systemic vasculitis are strongly associated with circulating antibodies to neutrophil cytoplasmic antigens (ANCA)
The diffuse cytoplasmic pattern (C-ANCA) is seen most typically in Granulomatosis with Polyangiitis. PR3 (proteinase 3) antibodies are thought to correspond to C-ANCA and act as a serological marker for disease activity with decline in the antibody level in remission
MPO (myeloperoxidase) antibodies in a large proportion of cases correspond to the P-ANCA seen by immunofluorescence.
MPO antibodies are seen in patients with a variety of vasculitic disorders, most notably patients with small vessel arteritis with renal impairment
In these patients MPO antibodies appear to be a good serological marker for disease activity as the antibody levels decline in remission
Sera of patients with acute pulmonary-renal syndrome or GPS like presentation will also be subjected to measurement of anti-glomerular basement membrane (GBM) antibodies
Urgent requests include:
Pulmonary renal syndrome, i.e. Good Pasteur’s syndrome (GPS) like presentation
Suspected Granulomatosis with Polyangiitis in kidney
Cerebrovascular events in young patients with clinical suspicion of vasculitic involvement
ANCA and GB tests can be performed urgently. Please contact the department if an urgent sample is being sent.
Allergy is a type I hypersensitivity reaction mediated by IgE together with inflammatory cells
Such a reaction could occur systemically (as in anaphylaxis) or could be localised to target organs (eye, airway mucosa etc)
Genetic predisposition to produce excessive amounts of IgE leading to allergy is termed atopy
Measurement of serum total IgE is a simple way to determine an individual’s atopic status
Diagnosis of allergy must be made in conjunction with clinical history and where possible supplemented with skin prick testing (SPT)
The Immunology department uses an automated system for allergy testing
It is an extremely specific and sensitive method and is used by the majority of laboratories in the UK
Low levels of IgE are normally accompanied by lower levels of specific IgE levels
Comparatively high levels of IgE often present higher levels of specific antigen reaction
This Department reports the total protein measured in kU/L.
The class is measured on a scale of 0 to 6. Class 0 and class 1 reactions represent an insignificant reaction whereas 2-6 have increasing significance, however there is no correlation between the grade and severity of the reaction since the presence of allergen specific IgE is a marker of exposure only, therefore a positive result can be observed in the absence of a clinical reaction
In addition levels of IgE fall when exposure is reduced, therefore low or negative results are shown in sensitised patients or in patients that have not had recent exposure
It should be noted also that if a reaction is highly localised there may be insufficient circulating IgE for detection
It is therefore crucial that allergy results are regarded with the clinical history of the patient
Some drug Specific IgE tests are available but if the determinants are limited (such as with penicillin) a negative result should not exclude allergy
Specific IgE investigations are conducted through the use of panel testing such as the common food panel or common airborne allergen panel
Where panels are positive individual allergens will be analysed
Mast cell tryptase indicates the level of mast cell degranulation that has occurred in serum
It is therefore a useful marker to establish whether an anaphylactic or adverse drug reaction has occurred
Three clotted specimens are required to assess the reaction (yellow top)
The first should be taken at the event, the second must be taken three hours post event and the final specimen should be taken 24 hours post event to measure baseline levels
Please ensure that all three specimens are clearly labelled with the respective time of phlebotomy
Immunodeficiency Investigations
It is advised that all patients with suspected primary immunodeficiency (PID) be referred to the Immunology Clinic
Please telephone the Department to discuss appropriate investigations and patient referral if required
Antiphospholipid antibodies, including anticardiolipin antibodies, are frequently detected in sera from patients with SLE. Numerous reports have associated these antibodies with various venous and arterial thrombosis disorders, including cerebral infarction, deep venous thrombosis, thrombocytopaenia, pulmonary embolism and recurrent foetal loss with placental infarction.
Cardiolipin antibody positive assay results require confirmation by repeat testing at least 12 weeks, to account for false-positive results (due to infection).
Primary Biliary Cholangitis (PBC) is a liver disease that damages bile ducts. Early treatment can help prevent liver failure. 90% of PBC patients are female middle aged and older. Smoking has also been found to be a risk factor.
Chronic hepatitis is an inflammation of the liver that lasts more than 6 months. Common causes of chronic hepatitis are Hep-B and C viruses, fatty liver disease, alcohol-related liver disease and certain drugs.
Positive liver autoantibody results will be called through for children (>18 years old) with raised LFTs.
Please ensure tubes are not used after their expiry date
Please ensure all tubes are stored within the temperature range of 4-25C (39-77F) before and after use
One yellow top specimen, SST clotted specimen, is normally sufficient for all requests for autoimmune and allergy investigations
Please ensure a separate yellow SST tube is taken for any Immunology requests
Haemolysed, lipaemic, contaminated (turbid), or icteric specimens may not be suitable for some investigations
Telephone the Department if further information is required regarding the performance of assays
Skin transport medium is available directly from the Department on request. Requests for skin transport medium from Immunology must be made at least 72 hours in advance from the time needed.
The medium contains a fixative and preservative and must be stored at room temperature.
Biopsies should be placed in skin transport medium for delivery to the Department on the same day. The medium will stabilise the tissue for up to 72 hours giving time for the sample to be referred onwards.
A 5mm punch biopsy taken from a non bullous region is required
A layer of intact epithelium is essential for interpretation
Please telephone the Department if these requirements cannot be fulfilled
A stool specimen is required for analysis
Specimens must be transported to the Immunology Department via the pneumatic pod or by Porter as soon as possible
If there is a delay please store specimens in a fridge until removal for delivery
Please ensure the sample vial is labelled correctly and the following patient details are provided on the pot first name, surname, date of birth, NHS or Hospital number. Please also include date and time of sample collection
Skin specimens transported in saline or formalin fixed specimen are inappropriate for direct immunofluorescence
If it is likely that the volume of blood is limited at venepuncture please contact the Department before phlebotomy to discuss the minimum volume of blood required for the request
This is particularly important for allergy tests where relatively large volumes of serum may be required
Please telephone the Department directly when requesting latex allergy tests so that patients going to theatre can be prioritised
In addition the Department would be grateful if the same information could be added to the request form
Three days notice is normally required to process these requests
Please refer to the adverse drug reaction protocol section of this document for guidelines regarding mast cell tryptase requests
The Department must receive C1 Esterase, AP50 and CH50 requests within six hours of phlebotomy
For mast cell tryptase requests, the Department must receive 3 specimens for testing for anaphylaxis including drug-related allergic reactions (e.g. perioperative anaphylaxis)
The first must be taken at the time of the event, the second must be taken three hours post event and the final sample should be taken 24 hours or greater post event (in order to measure baseline levels).
On average the Immunology Department stores samples for around 3 weeks
Please telephone the Department an urgent examination is required for a stored sample
Additional requests may be placed providing this is within this retention period
For any additional requests please contact the Department directly
These tests are performed ” in house ” and have a turn around time (TAT) of 14 days
Allergy Miscellaneous tests have a turn around time of 19 days
Individual allergens not provided in the table below may be available on request
IgE |
Measure of total IgE as an indicator of allergic reaction |
Nut panel |
Peanut, Hazelnut, Brazil Nut, Almond, Cocoa Nut |
Fish panel |
Cod, Shrimp, Blue Mussel, Tuna, Salmon |
Cereal panel |
Wheat, Oat, Maize, Sesame Seed, Buck Wheat |
General food panel |
Egg White, Milk, Cod Fish, Wheat, Peanut, Soya Bean |
Mixed fruit panel |
Apple, Banana, Peach, Pear |
Air-borne panel |
House Dust Mite, Timothy Grass, Birch Pollen, Cat Epithelium and Dander, Dog Dander |
Mould panel |
Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatis, Candida albicans, Alternaria alternata, Helminthosporium halodes |
Feather panel |
Budgie, Canary, Parakeet, Parrot, Finch |
Nuts |
Almond, Brazil, Cashew, Coconut, Hazel, Peanut, Pecan, Walnut, Chestnut, Pistachio, Pine nut, Macadamia |
Fish |
Blue Mussel, Crab, Tuna, Cod, Salmon, Shrimp, Mackerel, Lobster |
Cereal |
Maize, Oat, Rye, Sesame, Wheat, Buck Wheat, Barley |
Animals |
Cat epithelium and Dander, Dog Epithelium, Dog Dander, Guinea Pig, Hamster, Horse, Rabbit, Mixed Feathers |
Foods |
Advocado, Apple, Banana, Beef, Blackberries, Cacao, Carrot, Cheddar, Celery, Cherry, Chickpea, Chicken, Chillipepper, Egg White, Egg Yolk, Egg Whole, Garlic, Gluten, Kiwi, Lemon, Lentil, Maize, corn, Mango, Melon, Milk, Mushroom, Onion, Orange, Pea, Peach, Pear, Pineapple, Pork, Potato, Pumpkin Seed, Rape Seed, Rice, Sesame Seed, Soya, Strawberry, Tomato, Yeast, White Bean |
Plants |
Silver Birch, Timothy Grass, Pine Pollen |
Insects |
Honey Bee, House Dust Mite, Wasp |
Miscellaneous |
Aspergillus fumigatus, Latex Rubber, Penicilloyl G, Penicillin V, Suxamethonium, Chlorhexidine, Ampicilloyl, Amoxicilloyl, |
Recombinant Allergens |
rTri a 19 Omega-5 Gliadin, Wheat, rAra h 1 Peanut, rAra h 2 Peanut, rAra h 8 PR-10 Peanut, Cor a 8 hazel nut, nGal d 1 Ovomucoid |
Adverse Drug Reaction |
Mast Cell Tryptase (Turn around Time 16 days) |
Common Indicators |
Screening Test |
Follow Up |
---|---|---|
Acquired neuromyotonia |
Anti K+ gated channels |
|
Addisonian adrenal insufficiency |
Adrenal Abs |
|
Allergy |
Specific IgE to allergens (mixed allergen) |
|
Anti Phospholipid syndrome |
Anti Cardiolipin Antibody (IgG & IgM), B2 glycoprotein |
|
Avian precipitins |
Aspergillus Fumigatus (IgG), Pigeon Serum, Budgie Serum. |
|
C1-Esterase inhibitor deficiency |
C4/ C1-esterase antigenic and C1-esterase functional |
|
Chronic sensory neuropathies |
Anti MAG antibodies |
|
Chronic sensory neuropathy (IgM) |
Anti GQ1b antibodies |
|
Coeliac disease, Dermatitis herpetiformis |
Anti-TTG antibody |
Endomysial Antibodies |
Complement deficiency |
CH50 Functional AP50 |
|
Crest syndrome |
CTD |
DNA / ENA / Centromere Antibody |
Cystic fibrosis (CF) screen |
Candida albicans, Aspergillus Fumigatus (IgG). |
|
Dermatomyositis |
CTD |
DNA / ENA / JO |
Goodpasture’s syndrome |
Glomerular Basement Membrane Antibody (GBM) |
|
Graves’ and Hashimoto’s |
Thyroid Antibodies (TPO), TSH Receptor antibodies |
|
Guillain Barrè Syndrome |
Anti GM1 antibodies |
|
Idiopathic Addison’s disease |
Adrenal Antibodies |
|
Immunodeficiency |
Immunoglobulins (Biochemistry) |
|
Insulin dependent diabetes |
Anti-GAD & IA2 antibody |
|
Lambert-Eaton syndrome |
Anti Ca++ gated channels |
|
Mast cell degranulation following anaphylaxis |
Tryptase |
|
Microscopic polyangititis |
ANCA |
MPO |
Miller-Fisher syndrome (IgG) |
Anti GQ1b antibodies |
|
Multiflocal motor neuropathy |
Anti GM1 antibodies |
|
Myasthenia gravis |
Acetyl Choline Receptor Antibody |
MUSK |
Neonatal Lupus, Drug induced SLE |
CTD |
ENA DNA |
Neuromyelitis optica |
Aquaporin-4 Abs |
|
Pancreatitis & IgG4 related disease |
IGG subclasses / IGG4 |
|
Paraneoplastic syndromes |
Paraneoplastic Abs |
|
PBC |
Mitochondrial Abs |
M2 |
Pemphigoid / Pemphigus |
Skin antibodies (SKA) |
|
Pernicious Anaemia |
Intrinsic factor Abs |
I |
Polymyositis |
CTD |
ANA/Hep-2/ENA & Mi2-extended ENA Panel (In dermatomyositis |
Primary ovarian failure associated with autoimmune |
Ovarian Antibody |
|
Recurrent bacterial meningitis |
Complement Assay |
CH50 & AP50 |
Rheumatoid arthritis |
Rheumatoid factor (Biochemistry), CTD |
Anti-CCP antibody |
Scleroderma |
CTD, ENA Antibodies (SCL-70) DNA |
DNA/ENA/SCL70 |
Sjögren’s syndrome |
CTD |
ENA Antibodies (SSA – Ro) DNA |
SLE |
CTD |
DNA / ENA |
Stiff-man syndrome |
Anti-GAD Antibodies |
|
Subacute sensory neuropathy / limbic encephalitis |
Anti HU & anti YO antibodies |
|
Thyroiditis and primary hypothyroidism and associated endocrinopathies |
Thyroid Antibodies (TPO), |
|
Granulomatosis with polyangiitis |
PR3 MPO |
|
Tests outside the Immunology repertoire will be processed on a case by case basis
Please be aware that some of the following tests are confirmatory tests and their TAT reflects this
e.g. Endomysial antibody testing is performed following a first-time positive Tissue Transglutaminase antibody result or GAD testing performed first and IA2 testing completed if GAD result is negative.
Test Name |
Relevance |
Turn around time in days |
---|---|---|
Acetylcholine Receptor Abs |
Myasthenia Gravis |
21 days |
Adrenal Abs |
Addisonian adrenal insufficiency |
28 days |
Anti-β2-Glycoprotein IgG Abs |
Antiphospholipid syndrome |
7 days |
Anti-Centromere Abs |
CREST |
24 days |
Anti-Cyclic Citrullinated Peptide Antibody |
Rheumatoid Arthritis |
7 days |
Anti-nuclear Abs (connective tissue screen) |
Connective tissue disease |
7 days |
Anti-thyroid peroxidase Abs TPO |
Graves’ and Hashimoto’s |
7 days |
Voltage-gated calcium channel Abs |
Lambert Eaton myasthenic syndrome |
28 days |
Voltage-gated potassium channel Abs
CASPR2 and LGI1 |
Neurological disorders |
28 days |
Aquaporin-4 Abs |
Neuromyelitis optica |
28 days |
AP50 |
Alternative haemolytic complement assay |
28 days |
Liver autoimmune profile |
ANA – connective tissue disease |
10 days |
|
Liver / kidney microsomal Abs – Autoimmune hepatitis |
|
|
Mitochondria Abs- PBC |
|
|
Smooth muscle Abs- chronic active hepatitis |
|
Bronchiectasis |
Bronchiectasis screen |
40 days |
CH50 |
Haemolytic complement assay – classical pathway (liposomal method) |
28 days |
C1-esterase |
C1-Esterase inhibitor deficiency |
28 days |
C1-esterase functional |
C1-Esterase inhibitor deficiency |
56 days |
Anti- C1Q Abs |
Hypocomplementaemic Urticarial Vasculitis (HUV), Systemic Lupus Erythematosus(SLE)and Lupus Nephritis |
28 days |
C1Q level |
Differential diagnosis of acquired angioedema. Low levels can be seen in SLE, glomerulonephritis and recurrent infections |
28 days |
Cardiolipin IgG / IgM |
Antiphospholipid syndrome |
7 days |
Calprotectin |
Differentiates between Inflammatory Bowel Diseases, Crohn’s Disease and Ulcerative Colitis and other bowel diseases |
10 days |
Connective Tissue Disease (CTD) Screen |
Panel contains the following auto antibodies: |
7 days |
U1-snRNP |
||
Sm |
||
SS-A/Ro |
||
SS-B/La |
||
Centromere |
||
Jo-1 |
||
SCL-70 |
||
dsDNA |
||
Fibrillarin |
||
RNA Pol III |
||
Rib-P |
||
PM-Scl |
||
PCNA |
||
Mi-2 |
||
SmD |
||
Direct immunofluorescence (skin biopsies) |
Skin biopsy investigation for bullous disease,SLE, DH, EBA, Lichen planus |
14 days |
Double stranded DNA Abs |
SLE |
14 days |
Extractable nuclear antigens |
Screen |
14 days |
|
Ro – Sjogren’s, SLE |
|
|
La- Sjogren’s, SLE |
|
|
Sm – SLE specific |
|
|
RNP- MCTD, SLE |
|
|
Jo-1 – Polymyositis |
|
|
Scl-70 – Scleroderma |
|
Endomysial Abs (IgA) |
Coeliac Disease |
14 days |
Glomerular Basement Abs (GBM) |
Goodpasture’s Syndrome |
7 days |
Anti-Glutamic acid decarboxylase Abs (GAD) |
Type I diabetes and stiff mans syndrome |
28 days |
Anti-GM1 & GQ1B Abs |
Anti-ganglioside antibodies |
28 days |
Intrinsic Factor Abs |
Pernicious Anaemia |
14 days |
IA2 antibodies |
Type I diabetes |
56 days |
IGG subclasses / IGG4 |
Autoimmune pancreatitis and IgG4 associated diseases |
28 days |
Anti-MUSK |
Myasthenia Gravis |
49 days |
Mitochondrial 2 Abs (M2) |
Primary biliary cirrhosis |
14 days |
Anti-myelin associated glycoprotein Abs (MAG) |
Adult onset neuropathy |
28 days |
Fixed Cell NMDA receptor Abs |
Neurological disorders |
28 days |
Ovarian Abs |
Primary autoimmune ovarian failure |
28 days |
Myeloperoxidase Abs (MPO) |
(P-ANCA) Vasculitis |
Urgent 1 day, routine 7 days |
Proteinase 3 Abs (PR3) |
(C-ANCA) Granulomatosis with polyangiitis |
Urgent 1 day, routine 7 days |
Paraneoplastic Abs (includes Yo, Hu, Ri Antibodies) |
Paraneoplastic syndromes |
28 days |
Skin Abs |
Pemphigoid (Basement membrane – BM), Pemphigus. |
9 days |
Tissue Transglutaminase IgA |
Coeliac Disease |
7 days |
Tissue Transglutaminase IgG |
Coeliac Disease |
7 days |
TSH Receptor Antibodies |
Grave’s Disease |
14 days |
Please be aware that the following tests may be requested as further testing, based on the clinical details included in the request and clinical approval: